TCG Crossover III entities and Chen Yu have disclosed a shared beneficial ownership of 14,500,000 Ordinary Shares in InflaRx N.V. (IFRX), representing...
InflaRx (IFRX) reported new preclinical data indicating that its oral C5aR1 inhibitor, izicopan, generates low levels of reactive metabolites compared...
Bullish
InflaRx announced new preclinical data for its investigational C5aR1 inhibitor, izicopan, showing minimal reactive metabolite formation, suggesting a ...